Clinical trials: Impaired Left Ventricular Function
Premature Ventricular Contractions, Ventricular Dysfunction, Left
Prophylactic Frequent Premature Ventricular complexeS sUPPression on Left ventriculaR Function impairmEnt in aSymptomatic patientS
The main objective of the study is to demonstrate that prophylactic treatment of patients with asymptomatic frequent (>10%) PVCs is superior to simple follow-up strategy with no therapy to prevent subsequent LV dysfunction at 24…
- Trial name
- SUPPRESS (NCT05784051)
- Testing
- Experimental group, Control group
- Volunteers
- 298 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anthracycline-induced Cardiotoxicity, Lymphoma
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
- Conditions
- Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
- Trial name
- SPARTACUS (NCT07572175)
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Severe Isolated Left Ventricular Dysfunction, Severe Biventricular Dysfunction
Berlin Heart EXCOR Pediatric Post Approval Study
The purpose of this post-approval study of the EXCOR® Pediatric VAD is to evaluate whether safety and outcomes of the device use in the commercial setting are comparable to the safety and outcomes of the device use in the IDE…
- Trial name
- NCT01674699
- Testing
- EXCOR Pediatric
- Volunteers
- 49 people
- Sponsor
- Berlin Heart, Inc
Left Ventricular Dysfunction
PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
This study will be done in patients who require the implantation of a cardiac pacemaker (an electronic device that controls the heartbeat) for complete heart block (a heart rhythm abnormality resulting in a slow heart beat).
- Trial name
- PROTECT-PACE (NCT00461734)
- Testing
- RV lead placement site
- Where
- 18 sites in Australia, New Zealand and 1 more
- Volunteers
- 248 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure, Heart Failure With Reduced Ejection Fraction
AI-ECG for Time-Resolved Prediction of HFrEF
This study aims to develop and validate a deep learning-based electrocardiogram (ECG) model for predicting the future risk of heart failure with reduced ejection fraction (HFrEF).
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Left Ventricular Dysfunction, Cardiac Remodeling
- Trial name
- NCT07519434
- Where
- China
- Volunteers
- 286,709 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Heart Failure，Congestive, Cardiomyopathies
HIS-Purkinje Conduction System Pacing Optimized Trial of Cardiac Resynchronization Therapy
This is a randomized, prospective, single-blinded trial to determine the overall rate of successful His-Purkinje conduction system pacing Optimized Trial of Cardiac Resynchronization Therapy (HOT-CRT) versus biventricular pacing…
- Conditions
- Heart Failure，Congestive, Cardiomyopathies, Left Ventricular Dysfunction
- Trial name
- HOT-CRT (NCT04561778)
- Testing
- HOT-CRT, Biventricular Pacing
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Pugazhendhi Vijayaraman
Left Ventricular Function Systolic Dysfunction
Pacemaker Upgrade to Cardiac Resynchronisation Therapy in Patients With Left Ventricular Dysfunction Dependant Upon Right Ventricular Pacing
Patients with pacemakers often have undiagnosed heart muscle weakness. When a pacemaker battery has run down, it is easily replaced by a short procedure.
- Trial name
- PRE-Empt (NCT01652248)
- Testing
- Cardiac resynchronisation therapy
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Leeds
Chronic Myocardial Ischemia, Left Ventricular Dysfunction
Mesenchymal Stem Cells and Myocardial Ischemia
Ischemic cardiomyopathies are a leading cause of death in both men and women. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly, that…
- Trial name
- MESAMI (NCT01076920)
- Testing
- Mesenchymal stem cells
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Toulouse
Heart Failure, Revascularization
Percutaneous Coronary RevascularizatiOn VERsus Coronary-Artery Bypass Grafting for Multivessel Disease in Patients With Left Ventricular Dysfunction (PROVERB)
A short description, 5000 characters Ischemic cardiomyopathy related to coronary artery disease is currently the leading cause of heart failure.
- Trial name
- PROVERB (NCT05532631)
- Testing
- Percutaneous coronary intervention, Coronary artery bypass grafting
- Where
- France
- Volunteers
- 1,040 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Failure, Left Bundle-Branch Block
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with increased mortality, more frequent hospitalization…
- Conditions
- Heart Failure, Left Bundle-Branch Block, Ischemic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy
- Trial name
- RECOVER-HF (NCT05769036)
- Testing
- Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Biventricular Pacing, Implantation of Cardioverter-defibrillator with a Resynchronization Function Using Left Bundle Branch Pacing
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Left Ventricular Dysfunction, Coronary Artery Disease
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health…
- Trial name
- PROTECT IV (NCT04763200)
- Testing
- Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
- Where
- 110 sites in United States, Canada and 5 more
- Volunteers
- 1,252 people
- Sponsor
- Abiomed Inc.
Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
This study will evaluate whether adding Yiqi Fumai lyophilized injection to stable guideline-directed treatment improves symptoms, physical limitations, and NT-proBNP in adults with stable chronic heart failure caused by coronary…
- Conditions
- Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
- Trial name
- NCT07803471
- Testing
- Yiqi Fumai Lyophilized Injection(YQFM), Stable Guideline-Directed Medical Therapy
- Where
- 4 sites in China
- Volunteers
- 100 people
- Sponsor
- China Academy of Chinese Medical Sciences
COVID-19
Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors
Coronavirus Disease 2019 (COVID-19) emerged in December 2019, and in mere few months has resulted in a pandemic of viral pneumonia.
- Trial name
- NCT04355884
- Testing
- Standard 12-lead ECG, NT-proBNP, echocardiography
- Where
- Hong Kong
- Volunteers
- 100 people
- Sponsor
- The University of Hong Kong